Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated With Antitumor Angiogenesis Drugs: A WHO-VigiAccess Study

Abstract

Antiangiogenic therapy plays a critical role in cancer treatment. This study analyzed vascular and lymphatic adverse events linked to four FDA-approved agents—aflibercept, bevacizumab, olaratumab, and ramucirumab—using WHO-VigiAccess data. Disproportionality analysis (ROR and PRR) identified drug-specific risks, focusing on hypertension, hemorrhage, thrombosis, and flushing, to inform safer and personalized clinical use.